Rajesh K Malik

List of Publications by Year
in descending order

8	219	1684188 5	1720034 7
papers	citations	h-index	g-index

8	8	8	322
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2021, 87, 689-700.	2.3	9
2	Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer. International Journal of Cancer, 2021, 149, 1463-1472.	5.1	12
3	Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies. Cancer Management and Research, 2021, Volume 13, 6207-6218.	1.9	12
4	Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapyâ€induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials. Cancer Medicine, 2021, 10, 5748-5756.	2.8	26
5	CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy. , 2020, 8, e000847.		45
6	Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion. Science Translational Medicine, 2017, 9, .	12.4	107
7	First-in-human Phase 1 safety, PK, and PD study of the CDK4/6 inhibitor G1T28.. Journal of Clinical Oncology, 2015, 33, 2527-2527.	1.6	5
8	Evaluation of targeted bone marrow arrest by G1T28, a CDK4/6 inhibitor in clinical development to reduce chemotherapy-induced myelosuppression.. Journal of Clinical Oncology, 2015, 33, 2529-2529.	1.6	3